Could flickering lights and tones ease schizophrenia?
NCT ID NCT07342465
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tests whether a device that delivers synchronized 40 Hz light and sound (called GENUS) is safe and feasible for people with schizophrenia. The goal is to see if this at-home stimulation can improve brain rhythms, thinking, and symptoms that current medications don't fully address. Twenty participants will receive one hour of stimulation and undergo brain scans and cognitive tests.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gamma Entrainment Using Sensory Stimulation (GENUS) device delivering synchronized 40 Hz light and sound
What this could lead to
If it works, this could point toward a safe, at-home treatment to ease cognitive and negative symptoms of schizophrenia that current drugs often miss.
What could go wrong
This is a very early, small trial (20 people) focused on safety and feasibility, not proof of effectiveness. The benefits seen may not hold up in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA SPECTRUM DISORDERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Massachusetts Institute of Technology (MIT)
Cambridge, Massachusetts, 02139, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact